Ad-PUMA sensitizes ovarian cancer cells to chemotherapeutic agents
- PMID: 26698248
Ad-PUMA sensitizes ovarian cancer cells to chemotherapeutic agents
Abstract
Objective: Ovarian cancer accounted for the first cause of death in female reproductive system tumor even with the operation and chemotherapy. We sought to evaluate the therapeutic potential of p53 up-regulated modulator of apoptosis (PUMA) in ovarian cancer.
Materials and methods: An adenovirus expressing PUMA (Ad-PUMA), alone or in combination with chemotherapeutic agents, was used to treat two different ovarian cancer cell lines. The mechanism of PUMA-mediated growth suppression and apoptosis was investigated by analysis of caspase-9 activation and the change of mitochondrial membrane potential (Δψm).
Results: The exogenous PUMA was expressed 6 h after Ad-PUMA infection, which increased the chemosensitivity of the cancer cells and decreased the IC50 of chemotherapeutic agents compared with uninfected cells. The apoptotic percentage of OVCAR-3 and SKOV3 increased greatly compared with Taxol or Cisplatin alone. There was shear zone in caspase-9 and Δψm decrease after Ad-PUMA infection which suggested apoptosis started in mitochondrial mediated pathway.
Conclusions: PUMA plays a role in suppressing tumor growth and sensitizing ovarian cancer cells to anticancer drugs and may be a promising tool for cancer biotherapy.
Similar articles
-
Ad-PUMA sensitizes drug-resistant choriocarcinoma cells to chemotherapeutic agents.Gynecol Oncol. 2007 Dec;107(3):505-12. doi: 10.1016/j.ygyno.2007.08.007. Epub 2007 Sep 19. Gynecol Oncol. 2007. PMID: 17884151
-
A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA.Cancer Biol Ther. 2012 Jul;13(9):712-9. doi: 10.4161/cbt.20552. Epub 2012 May 23. Cancer Biol Ther. 2012. PMID: 22617775
-
PUMA sensitizes lung cancer cells to chemotherapeutic agents and irradiation.Clin Cancer Res. 2006 May 1;12(9):2928-36. doi: 10.1158/1078-0432.CCR-05-2429. Clin Cancer Res. 2006. PMID: 16675590
-
p53 gene status and chemosensitivity in ovarian cancer.Hum Cell. 2001 Sep;14(3):165-71. Hum Cell. 2001. PMID: 11774736 Review.
-
Addressing the challenge: current and future directions in ovarian cancer therapy.Curr Gene Ther. 2009 Dec;9(6):434-58. doi: 10.2174/156652309790031148. Curr Gene Ther. 2009. PMID: 20021329 Review.
Cited by
-
Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses.Porto Biomed J. 2018 Jun 29;3(1):e7. doi: 10.1016/j.pbj.0000000000000007. eCollection 2018 Aug. Porto Biomed J. 2018. PMID: 31595233 Free PMC article.
-
Inhibiting aberrant p53-PUMA feedback loop activation attenuates ischaemia reperfusion-induced neuroapoptosis and neuroinflammation in rats by downregulating caspase 3 and the NF-κB cytokine pathway.J Neuroinflammation. 2018 Sep 1;15(1):250. doi: 10.1186/s12974-018-1271-9. J Neuroinflammation. 2018. PMID: 30172256 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous